QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

PTGX

QT70Protagonist Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
112.86
+1.42+1.27%
OverviewShort InterestFilings
PTGXQT70Protagonist Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
112.86+1.27%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.81
Insider Own6.92%
Shs Outstand64.31M
Perf Week2.80%
Market Cap7.17BForward P/E-EPS next Y-0.89Insider Trans0.45%Shs Float-Perf Month14.73%
Enterprise Value6.98BPEG0.17EPS next Q2.43Inst Own-Short Float-Perf Quarter11.00%
Income-113236379.00P/S96.77EPS this Y322.85%Inst Trans-Short Ratio-Perf Half Y23.29%
Sales74.06MP/B11.07EPS next Y-122.07%ROA-16.45%Short Interest-Perf YTD29.22%
Book/sh10.19P/C-EPS next 5Y8.84%ROE-17.76%52W High114.49 -1.42%Perf Year104.42%
Cash/sh8.52P/FCF-EPS past 3/5Y-ROIC-21.29%52W Low49.38 128.55%Perf 3Y-
Dividend Est.-EV/EBITDA-61.29Sales past 3/5Y19.43% 9.67%Gross Margin99.45%Volatility2.21% 2.97%Perf 5Y-
Dividend TTM-EV/Sales94.28EPS Y/Y TTM-142.79%Oper. Margin-192.36%ATR (14)4.56Perf 10Y-
Dividend Ex-Date-Quick Ratio17.76Sales Y/Y TTM-82.95%Profit Margin-154.88%RSI (14)63.63Recom2.25
Dividend Gr. 3/5Y-Current Ratio17.76EPS Q/Q126.32%SMA209.37%Beta0.27Target Price117.25
Payout0.00%Debt/Eq0.01Sales Q/Q100.00%SMA5010.32%Rel Volume2.41Prev Close111.44
Employees124LT Debt/Eq0.01EarningsAug 05SMA20028.99%Avg Volume632.38KPrice112.86
IPO DateAug 11, 2016Option/ShortYes / YesEPS/Sales Surpr.107.69% 366.67%Net Debt/EBITDA1.61Volume1,524,436Change1.27%
Analyst Ratings
DateActionAnalystRatingTarget
May-06-26ReiteratedGoldman SachsNeutral$97 → $110
Apr-14-26ReiteratedTruist Financial$110 → $121
Mar-18-26ReiteratedJefferiesBuy$121
Jan-30-26ReiteratedH.C. WainwrightBuy$80 → $117
Jan-05-26ReiteratedTruist Financial$88 → $110
Dec-17-25ReiteratedBarclaysOverweight$72 → $108
Oct-28-25ReiteratedTruist Financial$76 → $88
Oct-13-25ReiteratedJohnson Rice$72 → $112
Oct-07-25ReiteratedJohnson Rice$62 → $74
Sep-16-25InitiatedBarclaysOverweight$72
Latest News
Jun-13-26
Jun-13-2609:30AM
Protagonist Therapeutics (NASDAQ:PTGX) Shows Technical Strength and High Growth MomentumChartMill
08:46AM
Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On GoalSeekingAlpha
Jun-12-26
Jun-12-2610:47AM
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug DataBenzinga
Jun-10-26
Jun-10-2612:12PM
Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue7446434
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A010
Gross Profit7445434
Selling, General and Administrative Excl. Other464543
Research and Development170159138
Other Operating Expense1-11
Operating Income-142-158253
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-27-29-27
Net Income Before Taxes-116-129279
Income Taxes-114
Consolidated Net Income-114-130275
Net Income From Continuing Operations-114-130275
Net Income-114-130275
EPS (Recurring)-1.80-2.054.47
EPS (Basic, Before Extraordinaries)-1.80-2.054.47
EPS (Diluted)-1.81-2.054.23
EBITDA-113-128280
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio99.13121.52—
Gross Margin100.0097.83100.00
Operating Margin-191.89-343.4858.29
Net Margin-154.05-282.6163.36
Shares Outstanding656462
Market Capitalization7,3365,590—
Operating Lease Expense
———
Insider Trading Volume
$116.95$108.08$99.21$90.34$81.47● Close Price0.00M3.58M7.16M10.74M14.32MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Waddill William D.DirectorJun 10 '26Option Exercise14.9618,000269,28016,825Jun 11 12:00 AM
Waddill William D.DirectorJun 10 '26Sale107.689,000969,1207,825Jun 11 12:00 AM
Waddill William D.DirectorMay 29 '26Option Exercise11.8018,000212,40016,825Jun 01 12:00 AM
Waddill William D.DirectorMay 29 '26Sale99.649,000896,7607,825Jun 01 12:00 AM
PATEL DINESH V PH DPresident and CEOMay 12 '26Option Exercise21.58150,0003,237,000598,478May 12 12:00 AM
PATEL DINESH V PH DPresident and CEOMay 12 '26Sale100.1275,0007,509,000523,478May 12 12:00 AM
Giraudo BryanDirectorMay 08 '26Sale100.0011,1301,113,0000May 11 12:00 AM
Giraudo BryanDirectorMay 07 '26Option Exercise6.6372,000477,12043,825May 11 12:00 AM
Giraudo BryanDirectorMay 07 '26Sale100.1248,0004,805,8806,000May 11 12:00 AM
Ali AsifChief Financial OfficerApr 20 '26Sale105.471,750184,57359,003Apr 21 12:00 AM
MOLINA ARTURO MDChief Medical OfficerMar 26 '26Option Exercise8.0430,000241,20099,115Mar 27 12:00 AM
MOLINA ARTURO MDChief Medical OfficerMar 26 '26Sale104.7915,0001,571,85084,115Mar 27 12:00 AM
SELICK HAROLD EDirectorMar 26 '26Option Exercise12.8848,000618,24084,845Mar 27 12:00 AM
SELICK HAROLD EDirectorMar 26 '26Sale105.0024,0002,520,00060,845Mar 27 12:00 AM
Ali AsifChief Financial OfficerMar 26 '26Option Exercise17.7049,530876,56085,518Mar 27 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR